Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
Theranostics · 2023
DOI: 10.7150/thno.84865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2023. Verfasst von Maria Vlastara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Radioimmunodetection, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands.
- SyMO-Chem, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands.
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Zitieren
APA
Vlastara, M., Rossin, R., Hoeben, F. J. M., de Roode, K. E., Boswinkel, M., Kleijn, L. H. J., Nagarajah, J., Rijpkema, M., & Robillard, M. S. (2023). Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics. https://doi.org/10.7150/thno.84865
Vancouver
Vlastara M, Rossin R, Hoeben FJM, de Roode KE, Boswinkel M, Kleijn LHJ, et al. Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio. Theranostics. 2023. doi:10.7150/thno.84865
BibTeX
@article{Vlastara2023,
author = {Vlastara, Maria and Rossin, Raffaella and Hoeben, Freek J M and de Roode, Kim E and Boswinkel, Milou and Kleijn, Laurens H J and Nagarajah, James and Rijpkema, Mark and Robillard, Marc S},
title = {Click-to-Release: Cleavable Radioimmunoimaging with [ 89 Zr]Zr-DFO- Trans -Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio},
journal = {Theranostics},
year = {2023},
doi = {10.7150/thno.84865}
}
EUVIMED